OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Thomas Yau, Vittorina Zagonel, Armando Santoro, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 9, pp. 1747-1757
Open Access | Times Cited: 45
Thomas Yau, Vittorina Zagonel, Armando Santoro, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 9, pp. 1747-1757
Open Access | Times Cited: 45
Showing 1-25 of 45 citing articles:
Biomarkers for immunotherapy of hepatocellular carcinoma
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 780-798
Closed Access | Times Cited: 99
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 780-798
Closed Access | Times Cited: 99
TKIs in combination with immunotherapy for hepatocellular carcinoma
Bernardo Stefanini, Luca Ielasi, Rusi Chen, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 3, pp. 279-291
Closed Access | Times Cited: 87
Bernardo Stefanini, Luca Ielasi, Rusi Chen, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 3, pp. 279-291
Closed Access | Times Cited: 87
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 4, pp. 310-322
Closed Access | Times Cited: 32
Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 4, pp. 310-322
Closed Access | Times Cited: 32
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 31
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 31
Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma
Narayanan Sadagopan, Aiwu Ruth He
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1259-1259
Open Access | Times Cited: 18
Narayanan Sadagopan, Aiwu Ruth He
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1259-1259
Open Access | Times Cited: 18
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Anwaar Saeed, Robin Park, Harsh B. Pathak, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Anwaar Saeed, Robin Park, Harsh B. Pathak, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
Yuming Shi, Erfan Taherifard, A.I. Saeed, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5965-5983
Open Access | Times Cited: 7
Yuming Shi, Erfan Taherifard, A.I. Saeed, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5965-5983
Open Access | Times Cited: 7
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma
Juan Jose Urquijo-Ponce, Carlos Alventosa-Mateu, Mercedes Latorre-Sánchez, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 19, pp. 2512-2522
Open Access | Times Cited: 6
Juan Jose Urquijo-Ponce, Carlos Alventosa-Mateu, Mercedes Latorre-Sánchez, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 19, pp. 2512-2522
Open Access | Times Cited: 6
Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma
Ghazaal Roozitalab, Behnaz Abedi, Saber İmani, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 3, pp. 889-918
Closed Access | Times Cited: 5
Ghazaal Roozitalab, Behnaz Abedi, Saber İmani, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 3, pp. 889-918
Closed Access | Times Cited: 5
Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
Bowen Dai, Jiaping Jiang, Xiaoyu Yu, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Bowen Dai, Jiaping Jiang, Xiaoyu Yu, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
Ke Jiang, Miaowen Liu, Xiao Zhao, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Ke Jiang, Miaowen Liu, Xiao Zhao, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2950-2950
Open Access | Times Cited: 10
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2950-2950
Open Access | Times Cited: 10
Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage
Lixia Ma, Yu Zhang, Yong Fang, et al.
Investigational New Drugs (2025)
Closed Access
Lixia Ma, Yu Zhang, Yong Fang, et al.
Investigational New Drugs (2025)
Closed Access
Validation of an albumin-indocyanine green-based China liver cancer staging system to evaluating resectable hepatocellular carcinoma patients and comparison with the Child-Pugh-based China liver cancer staging system
M S Chen, Chao Ren, MengXia Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
M S Chen, Chao Ren, MengXia Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma
L. Gramantieri, Annapaola Montagner, Andrea Arleo, et al.
ESMO Open (2025) Vol. 10, Iss. 3, pp. 104289-104289
Open Access
L. Gramantieri, Annapaola Montagner, Andrea Arleo, et al.
ESMO Open (2025) Vol. 10, Iss. 3, pp. 104289-104289
Open Access
Evolving landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025
Karan Kumar, Vivek A. Saraswat
Journal of Clinical and Experimental Hepatology (2025), pp. 102547-102547
Closed Access
Karan Kumar, Vivek A. Saraswat
Journal of Clinical and Experimental Hepatology (2025), pp. 102547-102547
Closed Access
PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers
Peishuang Xu, Chang Hong, Li Liu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189334-189334
Closed Access
Peishuang Xu, Chang Hong, Li Liu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189334-189334
Closed Access
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
John D. Gordan, Bridget P. Keenan, Huat Chye Lim, et al.
Drugs (2023) Vol. 83, Iss. 12, pp. 1091-1109
Closed Access | Times Cited: 9
John D. Gordan, Bridget P. Keenan, Huat Chye Lim, et al.
Drugs (2023) Vol. 83, Iss. 12, pp. 1091-1109
Closed Access | Times Cited: 9
Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
Yamin Shu, Ying Tang, Yufeng Ding, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110543-110543
Open Access | Times Cited: 8
Yamin Shu, Ying Tang, Yufeng Ding, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110543-110543
Open Access | Times Cited: 8
Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
Huawei Li, Jia You, Yuanfeng Wei, et al.
Phytomedicine (2023) Vol. 123, pp. 155189-155189
Closed Access | Times Cited: 8
Huawei Li, Jia You, Yuanfeng Wei, et al.
Phytomedicine (2023) Vol. 123, pp. 155189-155189
Closed Access | Times Cited: 8
A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors
Congjun Zhang, Jingjing Li, Hongyang Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Congjun Zhang, Jingjing Li, Hongyang Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies
Yusra Zarlashat, Hafiz Salman Mushtaq, Linh Pham, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6830-6830
Open Access | Times Cited: 2
Yusra Zarlashat, Hafiz Salman Mushtaq, Linh Pham, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6830-6830
Open Access | Times Cited: 2
Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study
Xiumei Jiang, Pan Wang, Ke Su, et al.
Annals of Hepatology (2024), pp. 101578-101578
Open Access | Times Cited: 2
Xiumei Jiang, Pan Wang, Ke Su, et al.
Annals of Hepatology (2024), pp. 101578-101578
Open Access | Times Cited: 2
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
Giulia Francesca Manfredi, Ciro Celsa, Chloe John, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1955-1971
Open Access | Times Cited: 6
Giulia Francesca Manfredi, Ciro Celsa, Chloe John, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1955-1971
Open Access | Times Cited: 6
